Aged blood
Phase 2Biologic
Aged blood is one of 37 biologic programs targeting Adverse Effect. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
47 competitors in Adverse Effect
#DrugCompanyPhaseTrials
1Arcoxia
NovartisApproved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Indocin
LLife Extension Foundation Inc.
Approved
Oxycontin
PProtega
Approved
Eldepryl
QQuagen
Approved
Pulmicort
SSalix
Approved
Truvada
GileadApproved
Salbutamol
GSKApproved
Salmeterol Fluticasone
AstraZenecaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aged blood. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- EEmory University